Ann: Company Update, page-11

HYGEA delayed a concern, UK looks promising addition to bottom line revenue in the next 12months. Provider agreements in the US increasing, should increase base line revenue over time.

US services income looks about 1.5mio USD for the quarter based on this update and increasing MoM. FDA moving forward - another 6-12months for approval.

NASDAQ on hold - obviously waiting on boost in revenue or regulatory changes in NMPA - process has been complicated again and again and is obviously a very rigorous testing process - another 3month delay from the passing away of its principal investigator.

MOUs in place except for MEDTL which was cancelled yesterday.

Tough breaks on the NMPA at the moment, but rest reads quite well.